Conformation-dependent blockage of activated VWF improves outcomes of traumatic brain injury in mice

Xin Xu,Chenyu Wang,Yingang Wu,Katie Houck,Tristan Hilton,Ashley Zhou,Xiaoping Wu,Cha Han,Mengchen Yang,Wei Yang,Fu-Dong Shi,Moritz Stolla,Miguel A. Cruz,Min Li,Jianning Zhang,Jing-fei Dong
DOI: https://doi.org/10.1182/blood.2020007364
IF: 20.3
2021-01-28
Blood
Abstract:Abstract Traumatic brain injury-induced coagulopathy (TBI-IC) causes life-threatening secondary intracranial bleeding. Its pathogenesis differs mechanistically from that of coagulopathy arising from extracranial injuries and hemorrhagic shock, but it remains poorly understood. We report results of a study designed to test the hypothesis that von Willebrand factor (VWF) released during acute TBI is intrinsically hyperadhesive because its platelet-binding A1-domain is exposed and contributes to TBI-induced vascular leakage and consumptive coagulopathy. This hyperadhesive VWF can be selectively blocked by a VWF A2-domain protein to prevent TBI-IC and to improve neurological function with a minimal risk of bleeding. We demonstrated that A2 given through intraperitoneal injection or IV infusion reduced TBI-induced death by >50% and significantly improved the neurological function of C57BL/6J male mice subjected to severe lateral fluid percussion injury. A2 protected the endothelium from extracellular vesicle-induced injury, reducing TBI-induced platelet activation and microvesiculation, and preventing a TBI-induced hypercoagulable state. A2 achieved this therapeutic efficacy by specifically blocking the A1 domain exposed on the hyperadhesive VWF released during acute TBI. These results suggest that VWF plays a causal role in the development of TBI-IC and is a therapeutic target for this life-threatening complication of TBI.
hematology
What problem does this paper attempt to address?